US stock futures flounder amid tech weakness, Fed caution
Sarepta Therapeutics Inc. (NASDAQ:SRPT) shares have tumbled to a 52-week low, with the stock price hitting $57.22, marking a significant downturn for the $6.06 billion biopharmaceutical company. According to InvestingPro data, the stock’s RSI indicates oversold territory, while analysts maintain price targets ranging from $70 to $215. Over the past year, Sarepta’s stock has witnessed a steep decline, with a 1-year change showing a substantial drop of 50.34%. Despite these challenges, the company maintains strong fundamentals with revenue growth of 53% and a healthy current ratio of 4.2. This downturn reflects investor concerns and market reactions to various challenges faced by the company, including competitive pressures and regulatory hurdles. The 52-week low serves as a critical indicator for investors tracking the company’s performance and considering the stock’s potential for rebound or further decline. For deeper insights into Sarepta’s valuation and 15+ additional ProTips, check out the comprehensive analysis available on InvestingPro.
In other recent news, Sarepta Therapeutics has faced several noteworthy developments. The company is preparing to report its first-quarter earnings for 2025, with analysts at H.C. Wainwright anticipating solid results due to the demand for ELEVIDYS, a gene therapy approved in June 2024. However, concerns have emerged following a patient death linked to ELEVIDYS, prompting the European Medicines Agency to place a clinical hold on the drug’s studies. This incident has led to Needham lowering its price target for Sarepta from $202 to $183, although the firm maintains a Buy rating.
UBS also reaffirmed a Buy rating with a $188 target, despite acknowledging the uncertainty introduced by the patient death. Meanwhile, H.C. Wainwright upgraded Sarepta’s stock from Sell to Neutral, setting a price target of $75, citing the stock’s alignment with the firm’s valuation expectations. The analyst remains cautious about Sarepta’s revenue prospects for the second half of 2025, particularly due to safety concerns that may affect ELEVIDYS’s adoption.
Additionally, the broader biotech sector, including Sarepta, has experienced volatility following the resignation of FDA’s top vaccine official, Peter Marks. This shakeup has raised concerns about potential changes in the regulatory landscape, impacting investor sentiment across the industry. Despite these challenges, Sarepta’s developments continue to be closely monitored by investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.